Omega Therapeutics, Inc. Uncategorized Contracts & Agreements
21 Contracts & Agreements
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Prologue Medicines, Inc. (formerly Flagship Labs 89, Inc.), effective November 18, 2024 (Filed With SEC on November 14, 2024)
- Shared Space Arrangement by and between Omega Therapeutics, Inc. and Flagship Labs 107, Inc., effective November 18, 2024 (Filed With SEC on November 14, 2024)
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Apriori Bio, Inc., effective November 18, 2024 (Filed With SEC on November 14, 2024)
- Shared Space Arrangement by and between Omega Therapeutics, Inc. and Flagship Labs 104, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Shared Space Arrangement by and between Omega Therapeutics, Inc. and Flagship Labs 101, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Prologue Medicines, Inc. (formerly Flagship Labs 89, Inc.), effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Metaphore Biotechnologies, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Apriori Bio, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Shared Space Agreement, dated August 1, 2024 by and between Omega Therapeutics, Inc. and Flagship Labs 97, Inc (Filed With SEC on August 6, 2024)
- Amendment, dated June 17, 2024 to Shared Space Agreement, dated July 12, 2023, by and between Omega Therapeutics, Inc. and Flagship Labs 89, Inc. (now known as Prologue Medicines,... (Filed With SEC on August 6, 2024)
- Amendment, dated June 17, 2024 to Shared Space Agreement, dated July 11, 2023, by and between Omega Therapeutics, Inc. and Apriori Bio, Inc (Filed With SEC on August 6, 2024)
- Amendment, dated June 17, 2024 to Shared Space Agreement, dated July 12, 2023, by and between Omega Therapeutics, Inc. and Metaphore Biotechnologies, Inc (Filed With SEC on August 6, 2024)
- Open Market Sale Agreement, dated as of August 3, 2023, between Omega Therapeutics, Inc. and Jefferies LLC (Filed With SEC on August 3, 2023)
- Shared Space Arrangement, dated as of July 12, 2023, by and between Omega Therapeutics, Inc. and Flagship Labs 89, Inc (Filed With SEC on July 13, 2023)
- Shared Space Arrangement, dated as of July 11, 2023, by and between Omega Therapeutics, Inc. and Apriori Bio, Inc (Filed With SEC on July 13, 2023)
- Shared Space Arrangement, dated as of July 12, 2023, by and between Omega Therapeutics, Inc. and Metaphore Biotechnologies, Inc (Filed With SEC on July 13, 2023)
- Amendment to Shared Space Agreement between Omega Therapeutics, Inc. and Senda Biosciences, Inc., dated January 31, 2022 (Filed With SEC on March 10, 2022)
- Shared Space Arrangement between Kintai Therapeutics, Inc. (n/k/a Senda Biosciences, Inc.) and the Registrant, dated July 13, 2020 (Filed With SEC on July 26, 2021)
- Offer Letter between Roger Sawhney and the Registrant, dated March 25, 2020 (Filed With SEC on July 9, 2021)
- Offer Letter between Tom McCauley and the Registrant, dated July 10, 2019 (Filed With SEC on July 9, 2021)
- Offer Letter between Mahesh Karande and the Registrant, dated March 2, 2019 (Filed With SEC on July 9, 2021)
